Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 26:13:586-91.
eCollection 2014.

Nesfatin-1: role as possible new anti-obesity treatment

Carmine Finelli  1 , Giuseppe Martelli  2 , Rocco Rossano  2 , Maria Carmela Padula  2 , Nicolina La Sala  1 , Luigi Sommella  3 , Giovanni Tarantino  4
Affiliations
Review

Nesfatin-1: role as possible new anti-obesity treatment

Carmine Finelli et al. EXCLI J. .

Abstract

In this article, we review on the current concepts about Nesfatin-1 as a new anti-obesity treatment and evaluate the existing issues in the context of this knowledge and the available literature. The intent is to enable clinicians to know Nesfatin-1 as a new anti-obesity treatment and make rational decisions based on this perspective as possible clinical application. Future research should seek to clarify whether Nesfatin-1 would be beneficial in the management of obesity.

Keywords: drug treatment; nesfatin-1; obesity.

PubMed Disclaimer

References

    1. Albayrak A, Demiryilmaz I, Albayrak Y, Aylu B, Ozogul B, Cerrah S, et al. The role of diminishing appetite and serum nesfatin-1 level in patients with burn wound infection. Iran Red Crescent Med J. 2013;15:389–392. - PMC - PubMed
    1. Chen P, Hover CV, Lindberg D, Li C. Central urocortin 3 and type 2 corticotropin-releasing factor receptor in the regulation of energy homeostasis: critical involvement of the ventromedial hypothalamus. Front Endocrinol. 2013;3:180. - PMC - PubMed
    1. Dong J, Xu H, Xu H, Wang PF, Cai GJ, Song HF, et al. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 2013;8:e83397. - PMC - PubMed
    1. Doyon C, Moraru A, Richard D. The corticotropin-releasing factor system as a potential target for antiobesity drugs. Drug News Perspect. 2004;17:505–517. - PubMed
    1. Finelli C, Padula MC, Martelli G, Tarantino G. Could the improvement of obesity-related co-morbidities, following bariatric surgery, depend on modified gut hormones secretion? World J Gastroenterol. 2014, in press - PMC - PubMed

LinkOut - more resources